Piroxicam in the treatment of primary dysmenorrhea.
In double-blind, crossover studies, piroxicam was compared with naproxen sodium and with placebo. The different parameters studied were pain intensity, patient's opinion of the drugs tested, complementary pharmacological treatment, ability to work, overall effect, treatment preference, and side effects. It was concluded that piroxicam was comparable to naproxen sodium and that piroxicam was significantly better than placebo, as regards these parameters. It was also concluded that piroxicam has an effect equivalent to that of naproxen sodium, an accepted treatment for dysmenorrhea.
D000293:Adolescent; D000328:Adult; D000700:Analgesics / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004412:Dysmenorrhea / Q000188:drug therapy*; D005260:Female; D006801:Humans; D009288:Naproxen / Q000009:adverse effects / Q000627:therapeutic use; D010894:Piroxicam; D011897:Random Allocation; D013843:Thiazines / Q000009:adverse effects / Q000627:therapeutic use*
D000700:Analgesics; D013843:Thiazines; D010894:Piroxicam; D009288:Naproxen